Streetwise Reports' Article Archives — June 2018 back to current month (10)
Coverage Initiated on Biopharma with 'Opioid Sparing Solution for Post-Op Pain' (06/27/2018)
An H.C. Wainwright & Co. report highlighted the advantages, status and potential of this lead asset.
Immunotherapy Firm's Triple Combination Trial for Glioblastoma Sees First Patient Dosed (06/27/2018)
A Maxim Group note discussed the latest clinical endeavor involving a three-pronged approach targeting glioblastoma.
Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase (06/26/2018)
This precision medicine company, focused on neurodegenerative diseases, has selected antibody candidates to advance into the final phase of discovery.
Agreement Facilitates Progress Toward Medical Device Approvals (06/20/2018)
This medical device company enters a partnership to provide quality and regulatory services.
Coverage Initiated on Immunotherapy Developer with Phase 3 Lead Asset (06/20/2018)
A B. Riley FBR report provided an overview of this life sciences firm.
Transfusion Medicine Biotech Hits Target on Road to Commercialization (06/20/2018)
A BTIG report reviewed the news announced by this supplier of blood grouping reagents and control products.
Biotech Targeting Alzheimer's Disease Advances Toward Phase 1 (06/13/2018)
Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease.
Biotech Releases 'Unequivocally Positive' Topline NASH Study Results (06/13/2018)
An H.C. Wainwright & Co. report relayed the highlights of the new trial data from this Israel-based firm.
Mobile Health Platform Firm Signs Deal That Will Increase Pace of Onboarding Patients (06/06/2018)
A technology company that develops mobile health and telemedicine platforms for community-based healthcare has raised money, made a deal that will accelerate the number of patients it adds every month, and is breaking through its hardware logjam.
Biotech Consolidates Shares in Preparation for NASDAQ Listing (06/05/2018)
A Canaccord Genuity analyst provided an update on this late-stage Canadian life sciences firm targeting metastatic breast cancer.
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec